PMID: 42442380

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

Turner Nicholas C, Mayer Erica L, Park Yeon Hee, Janni Wolfgang, Ma Cynthia, Cristofanilli Massimo, Bianchini Giampaolo, Kalinsky Kevin, Iwata Hiroji, Chia Stephen

The Lancet. Oncology · 2026

Vol. 27, Issue 8, pp. 941-958

View on PubMed DOI

This entry links to third-party literature. For research use only.

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.